Literature DB >> 2873281

Graft rejection and graft-versus-host disease: mirror images.

R P Gale, Y Reisner.   

Abstract

Graft rejection and graft-versus-host disease (GvHD) complicate bone marrow transplantation in animals and man. The likelihood of each correlates with the degree of genetic disparity between donor and recipient. However, instead of a direct relation between graft rejection and GvHD, these events are inversely correlated: in most instances, they are mutually exclusive. A similar, complex relation exists with a third possible event, graft-versus-leukaemia. Attempts to suppress graft rejection or GvHD are likely to increase the reciprocal outcomes unless additional measures are instituted.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2873281     DOI: 10.1016/s0140-6736(86)91503-5

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  15 in total

1.  Selective resistance of bone marrow-derived hemopoietic progenitor cells to gliotoxin.

Authors:  A Müllbacher; D Hume; A W Braithwaite; P Waring; R D Eichner
Journal:  Proc Natl Acad Sci U S A       Date:  1987-06       Impact factor: 11.205

2.  Induction of tolerance to bone marrow allografts by donor-derived host nonreactive ex vivo-induced central memory CD8 T cells.

Authors:  Eran Ophir; Yaki Eidelstein; Ran Afik; Esther Bachar-Lustig; Yair Reisner
Journal:  Blood       Date:  2009-12-30       Impact factor: 22.113

Review 3.  The lost chord: microchimerism and allograft survival.

Authors:  T E Starzl; A J Demetris; N Murase; M Trucco; A W Thomson; A S Rao
Journal:  Immunol Today       Date:  1996-12

4.  Dendritic cells stimulate primary human cytolytic lymphocyte responses in the absence of CD4+ helper T cells.

Authors:  J W Young; R M Steinman
Journal:  J Exp Med       Date:  1990-04-01       Impact factor: 14.307

5.  Phase 2 clinical trial of rapamycin-resistant donor CD4+ Th2/Th1 (T-Rapa) cells after low-intensity allogeneic hematopoietic cell transplantation.

Authors:  Daniel H Fowler; Miriam E Mossoba; Seth M Steinberg; David C Halverson; David Stroncek; Hahn M Khuu; Frances T Hakim; Luciano Castiello; Marianna Sabatino; Susan F Leitman; Jacopo Mariotti; Juan C Gea-Banacloche; Claude Sportes; Nancy M Hardy; Dennis D Hickstein; Steven Z Pavletic; Scott Rowley; Andre Goy; Michele Donato; Robert Korngold; Andrew Pecora; Bruce L Levine; Carl H June; Ronald E Gress; Michael R Bishop
Journal:  Blood       Date:  2013-02-20       Impact factor: 22.113

6.  A new approach for eradication of residual lymphoma cells by host nonreactive anti-third-party central memory CD8 T cells.

Authors:  Assaf Lask; Eran Ophir; Noga Or-Geva; Adva Cohen-Fredarow; Ran Afik; Yaki Eidelstein; Shlomit Reich-Zeliger; Bar Nathansohn; Matthias Edinger; Robert S Negrin; David Hagin; Yair Reisner
Journal:  Blood       Date:  2013-02-27       Impact factor: 22.113

7.  Graft rejection as a Th1-type process amenable to regulation by donor Th2-type cells through an interleukin-4/STAT6 pathway.

Authors:  Jacopo Mariotti; Jason Foley; Kaitlyn Ryan; Nicole Buxhoeveden; Veena Kapoor; Shoba Amarnath; Daniel H Fowler
Journal:  Blood       Date:  2008-07-14       Impact factor: 22.113

8.  Hematopoietic stem cell transplantation across major genetic barriers.

Authors:  Yair Reisner
Journal:  Immunol Res       Date:  2007       Impact factor: 2.829

9.  IFN-gamma activation of mesenchymal stem cells for treatment and prevention of graft versus host disease.

Authors:  David Polchert; Justin Sobinsky; Gw Douglas; Martha Kidd; Ada Moadsiri; Eduardo Reina; Kristyn Genrich; Swati Mehrotra; Suman Setty; Brett Smith; Amelia Bartholomew
Journal:  Eur J Immunol       Date:  2008-06       Impact factor: 5.532

10.  Depletion of asialo-GM1+ cells from the F1 recipient mice prior to irradiation and transfusion of parental spleen cells prevents mortality to acute graft-versus-host disease and induction of anti-host specific cytotoxic T cells.

Authors:  K Varkila
Journal:  Clin Exp Immunol       Date:  1987-09       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.